DiaMedica Therapeutics Inc. (DMAC)
Track the next or latest earnings date for DiaMedica Therapeutics Inc., review consensus estimates, and see cached AI analysis for recent quarterly results.
Recent earnings news
www.stocktitan.net · 3 days ago
Independent DSMB will use the first 200 stroke patients to assess ReMEDy2 sample size, with interim analysis expected by end of 2026.
DiaMedica stroke trial reaches 75% of interim analysis threshold By Investing.comca.investing.com · 3 days ago
InvestingPro subscribers have access ... about DMAC, plus comprehensive Pro Research Reports covering over 1,400 US equities. DM199 is a recombinant form of human tissue kallikrein-1, a serine protease. The company is also developing the drug candidate for preeclampsia and fetal growth restriction. …
DiaMedica Therapeutics (DMAC) compare vs stock and Difference-between - Tickeron.comtickeron.com · 2 days ago
Find DiaMedica Therapeutics (DMAC) competitors. Compare which-is-better and find difference-between DMAC in performance, different metrics, and ratios. - Tickeron.com
McDonald's (MCD) Q1 2026 earningscnbc.com · 2 weeks ago
Shares of McDonald's have fallen 10% over the last year, hurt by concerns about the broader economy.
DiaMedica at 2026 RBC Global Healthcare Conference | DMAC Stock Newswww.stocktitan.net · 1 week ago
Fireside chat with CEO Rick Pauls at RBC’s 2026 Global Healthcare Conference, plus investor meetings as DiaMedica develops DM199, a KLK1 protein candidate.
Latest earnings date
Time not specified
Fiscal quarter: 2025-12-31
EPS estimate: -$0.17
Revenue estimate: N/A
Market cap: $372.87M
Analysis snapshot
No cached AI earnings analysis is available for this stock yet. Check back after the company reports or open the app to generate a fresh analysis.
Recent earnings history
Browse the calendar week| Date | Quarter | Report window | EPS est. | Revenue est. |
|---|---|---|---|---|
| Mar 16, 2026 | 2025-12-31 | Time not specified | -$0.17 | N/A |